DF/HCC Breast & Gynecologic Cancer Symposium

On Friday, March 29, 2024 the Susan F. Smith Center for Women’s Cancers  and the Breast and Gynecologic Programs in the DF/HCC will sponsor a day-long symposium to highlight breast and gynecologic cancer research at Harvard.

We invite all DF/HCC researchers who are doing work in breast and gynecologic cancers, including fellows, post-docs, and junior faculty to attend and to submit abstracts. 

2024 Agenda

March 29, 2024

Joseph B. Martin Conference Center 

Harvard Medical School 
77 Avenue Louis Pasteur
Boston MA, 02115



7:15 am

, Continental Breakfast, Poster Set-Up

8:00 am

Welcome/Purpose of Symposium
Susan F. Smith Center Leaders

8:10 am

J. Dirk Iglehart, M.D., Visiting Scholar Lecture
Harnessing omics and AI for precision breast oncology

Christina Curtis, PhD, MSc
RZ Cao Professor of Medicine, Genetics & Biomedical Data Science
Director AI and Cancer Genomics
Director, Breast Cancer Translational Research
Investigator, Chan Zuckerberg Biohub
Stanford University
(35-40 min talk, 10 mins questions)

9:00 am

SESSION I:Genomics
Chair: Gerburg Wulf

9:00 – 9:45 am

3 oral presentations (10 mins each; 5 mins questions)

Abstract #1
Okoh Frimpong: Chemoproteomic Evaluation of PROTACs Targeting Estrogen Receptor Alpha in ER+ Breast Cancer

Abstract #4               
Zheqi Li: KDM4C histone demethylase prevents histone cleavage in breast cancer

Abstract #9               
Jessica St. Laurent: Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in endometrioid carcinomas

9:45 am

9:45 am – 10:30 am – Open Posters

10:30 am

SESSION II: Risk, Prevention & Disparities/Clinical
Chair: Sara Tolaney

10:30 – 11:15 am

3 oral presentations (10 mins each; 5 mins questions)

Abstract #12             
Haohui Duan: BRCA2 haploinsufficiency induces P53 degradation in primary mammary epithelial cells – a crucial early event in breast tumor promotion

Abstract #18             
Jennifer Mongiovi: Associations between intrauterine device use and ovarian cancer risk among 11 population-based case-control studies

Abstract #21             
Xingping Qin: Safely targeting endogenous and therapy-enhanced BCL-XL dependence in ovarian cancer using the PROTAC DT2216

11:15 am

M. Patricia Cronin Memorial Lecture
Why listening to women matters in ovarian cancer research

Sarah M. Temkin, M.D.
Associate Director for Clinical Research
Office of Research on Women’s Health
Office of the Director, NIH
(35-40 min talk, 10 mins questions)

12:05 pm

Lunch and Open Posters
12:05 – 1:15pm

1:15 pm

SESSION III: Drug Resistance/Animal Models
Chair: Patricia Donahoe

1:15 – 2:15 pm

4 oral presentations (10 mins each; 5 mins questions)

Abstract #30             
Carman Li: Brca1 haploinsufficiency promotes early tumor onset and epigenetic alterations in a mouse model of hereditary breast cancer

Abstract #32             
Yusuke Matoba: Targeting Bcl-XL is a potential novel therapy for uterine serous cancer

Abstract #35             
Ramya Ravindranathan: PARG inhibitor sensitivity is correlated with accumulation of single strand DNA gaps in preclinical models of ovarian cancer

Abstract #40             
Ting Liu: Intratumoral heterogeneity drives resistance to Antibody Drug Conjugate therapy: Analysis of the NeoSTAR trial of neoadjuvant Sacituzumab govitecan for localized TNBC.

2:15 pm

SESSION IV: Tumor Microenvironment/Immunology
Chair: Jean Zhao

2:15 – 3:00 pm

3 oral presentations (10 mins each; 5 mins questions)

Abstract #41             
Sara Busatto: Breast cancer-derived extracellular vesicles modulate the endocytic metabolism and morphodynamics of the endothelial cells of the blood-brain barrier

Abstract #43             
Maeva Chauvin: Targeting Follistatin-like 3 to reverse immunotherapy resistance in ovarian cancer

Abstract #46             
Adam Nelson: Immune mediated mechanisms of PARPi resistance in BRCA1-associated triple negative breast cancer (TNBC)

3:00 pm

Announcement of Awards and Adjourn